Recent Updates
Recently added Catalysts

AGEN1571

Phase 1

Advanced Solid Tumor | Small molecule | Oncology |Agenus Inc.|Last Updated: Apr 30, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
CONTROLLED
Total Trials1
Total Enrollment22
FDA Designations
No designations recorded
Clinical trial landscape

AGEN1571 · 1 trial · 1 indication

Phase 1 1
NCT05377528Study of AGEN1571 in Participants With Advanced Solid TumorsAdvanced Solid Tumor
COMPLETED22 Analytics
PHASE1COMPLETED
Study of AGEN1571 in Participants With Advanced Solid Tumors
Advanced Solid Tumor
NCT0537752822
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number Of Participants With Dose-limiting Toxicities
Day 1 through Day 42
Number Of Participants With Treatment-emergent Adverse Events
Day 1 up to 12 months after the last dose
Secondary Endpoints
Serum AGEN1571 Concentration
Day 1 up to 90 days after the last dose
Serum Balstilimab Concentration
Day 1 up to 90 days after the last dose
Serum Botensilimab Concentration
Day 1 up to 90 days after the last dose
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Dose Escalation: AGEN1571EXPERIMENTALParticipants will receive AGEN1571 monotherapy.
Dose Escalation: AGEN1571 + BalstilimabEXPERIMENTALParticipants will receive AGEN1571 with balstilimab.
Dose Escalation: AGEN1571 + BotensilimabEXPERIMENTALParticipants will receive AGEN1571 with botensilimab.
Dose Escalation: AGEN1571 + Balstilimab + BotensilimabEXPERIMENTALParticipants will receive AGEN1571 with balstilimab and botensilimab.
Dose ExpansionEXPERIMENTALAGEN1571 administered at the RP2D for monotherapy or any combination therapy.
Interventions
NameTypeDescription
AGEN1571DRUGA fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
BalstilimabDRUGA fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.
BotensilimabDRUGA fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: 1. Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures (participation in genetic testing is optional). 2. Histologically confirmed diagnosis of a solid tumor that is currently metastatic or locally advance...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials (matched to "Advanced Solid Tumor")
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence